Captrust Financial Advisors Biocryst Pharmaceuticals Inc Transaction History

Captrust Financial Advisors

$33 Billion
Q3 2024

A detailed history of Captrust Financial Advisors transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Captrust Financial Advisors holds 16,274 shares of BCRX stock, worth $121,892. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,274

Previous 13,630 19.4%

Holding current value

$121,892

Previous $84,000 46.43%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $16,948 - $22,976	2,644 Added 19.4%	16,274 $123,000
Q2 2024 Aug 14, 2024	BUY	$4.13 - $6.79 $1,424 - $2,342	345 Added 2.6%	13,630 $84,000
Q1 2024 May 15, 2024	BUY	$4.89 - $7.65 $64,963 - $101,630	13,285 New	13,285 $67,000
Q2 2022 Aug 23, 2022	SELL	$7.89 - $17.88 $1,672 - $3,790	-212 Reduced 3.2%	6,421 $68,000
Q2 2022 Aug 16, 2022	BUY	$7.89 - $17.88 $362 - $822	46 Added 0.7%	6,633 $70,000
Q1 2022 May 16, 2022	BUY	$11.56 - $19.76 $3,941 - $6,738	341 Added 5.46%	6,587 $107,000
Q4 2021 Feb 14, 2022	SELL	$11.18 - $15.46 $17,563 - $24,287	-1,571 Reduced 20.1%	6,246 $87,000
Q3 2021 Nov 16, 2021	BUY	$14.21 - $17.65 $37,287 - $46,313	2,624 Added 50.53%	7,817 $112,000
Q1 2021 May 17, 2021	SELL	$7.37 - $13.61 $4,842 - $8,941	-657 Reduced 11.23%	5,193 $53,000
Q4 2020 Feb 16, 2021	SELL	$3.37 - $8.61 $4,212 - $10,762	-1,250 Reduced 17.61%	5,850 $44,000
Q3 2020 Nov 17, 2020	BUY	$3.43 - $5.53 $12,444 - $20,062	3,628 Added 104.49%	7,100 $25,000
Q2 2020 Aug 14, 2020	BUY	$1.9 - $5.61 $6,596 - $19,477	3,472 New	3,472 $17,000

Others Institutions Holding BCRX

# of Institutions

279

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.39B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.

Account

Captrust Financial Advisors Biocryst Pharmaceuticals Inc Transaction History